CASI Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
CASI Pharmaceuticals has a total shareholder equity of $13.8M and total debt of $19.1M, which brings its debt-to-equity ratio to 138.1%. Its total assets and total liabilities are $63.6M and $49.8M respectively.
Key information
138.1%
Debt to equity ratio
US$19.12m
Debt
Interest coverage ratio | n/a |
Cash | US$20.81m |
Equity | US$13.85m |
Total liabilities | US$49.77m |
Total assets | US$63.62m |
Recent financial health updates
We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate
Sep 02Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?
May 20Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?
May 26Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?
May 25Recent updates
The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34%
Nov 26CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too
May 21Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%
Mar 12CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%
Dec 18We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate
Sep 02Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?
May 20Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M
Sep 23CASI Pharmaceuticals Q2 2022 Earnings Preview
Aug 11Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?
May 26Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts
Aug 14Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?
May 25Financial Position Analysis
Short Term Liabilities: CASI's short term assets ($47.2M) exceed its short term liabilities ($14.7M).
Long Term Liabilities: CASI's short term assets ($47.2M) exceed its long term liabilities ($35.0M).
Debt to Equity History and Analysis
Debt Level: CASI has more cash than its total debt.
Reducing Debt: CASI's debt to equity ratio has increased from 0% to 138.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if CASI has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CASI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 14:16 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CASI Pharmaceuticals, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Justin Zelin | BTIG |
Nathaniel Calloway | Edison Investment Research |
Ching-Yi Lin | H.C. Wainwright & Co. |